|Telmisartan||Angiotensin II receptor antagonist|
|Trade names||MicardisPlus, Micardis HCT, others|
|Defined daily dose||Not established|
Telmisartan/hydrochlorothiazide, sold under the names Micardis HCT among others, is a medication used to treat high blood pressure. It is a combination of telmisartan an angiotensin II receptor antagonist with hydrochlorothiazide a diuretic. It may be used if telmisartan by itself is not sufficient. It is taken by mouth.
Common side effects include dizziness, upper respiratory tract infections, nausea, diarrhea, and tiredness. Severe side effects may include kidney problems, electrolyte problems, and allergic reactions. Use during pregnancy may harm the baby. Telmisartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by decreasing the kidneys' ability to retain water.
The combination was approved for medical use in the United States in 2000. The combination is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system. It is available as a generic medication. A month of medication costs the NHS about £17 as of 2018. In the United States it costs about US$65 per month as of 2019.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 10 September 2020.
- "DailyMed - TELMISARTAN AND HYDROCHLOROTHIAZIDE tablet". dailymed.nlm.nih.gov. Retrieved 29 October 2019.
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 178. ISBN 9780857113382.
- "Hydrochlorothiazide and telmisartan Uses, Side Effects & Warnings". Drugs.com. Retrieved 29 October 2019.
- "World Health Organization model list of essential medicines: 21st list 2019". 2019. hdl:10665/325771. Cite journal requires
- "Hydrochlorothiazide/telmisartan Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 29 October 2019.
- "Hydrochlorothiazide mixture with telmisartan". Drug Information Portal. U.S. National Library of Medicine.